Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.48 |
| ▸ | MET | P08581 | 16/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3566451 | 0.91 | KDR (0.55) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL307973 | 0.89 | KDR (0.47) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL306922 | 0.86 | KDR (0.46) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL896173 | 0.86 | KDR (0.51) | KDRMETFLT1 | |
| SCHEMBL3573701 | 0.86 | KDR (0.55) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL13168660 | 0.86 | KDR (0.44) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL27811860 | 0.85 | KDR (0.47) | KDRMETMAPTALDH1A1MAPK1 | |
| SCHEMBL3560489 | 0.85 | KDR (0.47) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL3566289 | 0.84 | KDR (0.44) | KDRMETMAPTFLT1ALDH1A1 | |
| SCHEMBL15225655 | 0.82 | KDR (0.44) | KDRMETMAPTFLT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | KDR 3/4885MET 2/4885MAPT 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.